艾迪持续动脉灌注联合栓塞治疗伴有肝细胞黄疸的肝脏恶性肿瘤  

Continuous transarterial infusion chemotherapy with Aidi combined with transhepatic arterial embolism in treatment of liver malignant tumor with hepatocellular jaundice

作　　者：靳冬民 郭玉晓[1] 胡鸿涛[2] 黎海亮[2] 郭晨阳[2] 郭旻[2] 

机构地区：[1]河南省嵩县中医院肿瘤科,河南471400 [2]河南省肿瘤医院放射科介入病房,450003

出　　处：《当代医学》2009年第29期556-557,共2页Contemporary Medicine

摘　　要：目的观察艾迪持续动脉灌注联合栓塞治疗伴有肝细胞黄疸的肝脏恶性肿瘤的临床疗效。方法对49例伴有肝细胞黄疸的原发肝癌和肝转移癌患者经左锁骨下动脉留置导管内灌注艾迪注射液并进行栓塞治疗。结果49例患者中,有1例死亡;2例中途放弃治疗,共46例完成治疗。0.5、1、2、3年生存率为89.1%(41/46),34.8%(16/46),17.4%(8/46),4.3%(2/46)。结论对于伴有肝细胞黄疸的原发肝癌和肝转移癌患者,使用艾迪持续动脉灌注联合栓塞可以在改善肝功能的前提下,有效的控制肿瘤,同时提高患者的免疫功能和生存率。Purpose To investigate the effect of continuous transarterial infusion chemotherapy with Aidi combined with transhepatic arterial embolism in treatment of liver malignant tumor. Methods Forty-nine cases with hepatocellular jaundice caused by primary hepatocarcinoma and hepatic metastasis were treated with continuous transarterial infusion chemotherapy with Aidi combined with transhepatic arterial embolism. Results In forty-nine cases, one was dead, two of them gave up during the treatment time, forty-six cases completed treatment. The 0.5-, 1-, 2-, 3-year survival rates were 89.1%, 34.8%, 17.4%, 4.3%. Conclusion For the cases with hepatocellular jaundice caused by primary hepatocarcinoma and hepatic metastasis, continuous transarterial infusion chemotherapy with Aidi combined with transhepatic arterial embolism is an effective way. It can improve the hepatic function, control tumor effectively and enhance immunity and survival rate.

关 键 词：艾迪 动脉灌注 肝细胞黄疸 肝脏恶性肿瘤 

分 类 号：R735.7[医药卫生—肿瘤] R473.73[医药卫生—临床医学]